Review Of The COVID-19 Vaccine Variants' Efficacy, Safety, And Tolerance For People Of Various Ages

Abdelsalam Abuzreda, Amenh B. Yousif, Hanan Alsgheer

Abstract


The COVID-19 pandemic has caused significant morbidity and mortality throughout the world, as well as major social, educational and economic disruptions. There is an urgent global need to make COVID-19 vaccines available at scale and equitably across all countries (1). The whole world currently faces an emergency health crisis, as a result of the spread of the new Corona virus (2).

The novel coronavirus is synonymous with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) due to its equitability (~80%) to SARS-CoV, resulting in acute respiratory distress syndrome (ARDS) associated mortality during 2002-2003. Several thousand people have already succumbed to the disease worldwide with higher mortality rates in the elderly. Current medical management is largely supportive with no targeted therapy available (3).


Keywords


COVID-19 Vaccine Variants' Efficacy, Safety, Tolerance, Various Ages.

Full Text:

PDF

References


W Habib, A Elhain, A Abuzreda. Assessing of practices and preventive measures for the environmental outbreak of the Corona pandemic: An Analytical study of sample workers in the city of Benghazi. global Libyan journal 2022; 56.

World health organization .Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac.2021;Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac (who.int).

C Ghantasala, A Abuzreda, AB Yousif .Reinfection And Non Transmission Of Covid 19- An Unusual Case Report. Indian Journal of Research.2021;10:3.

4.Wang, J., Tong, Y., Li, D., Li, J., & Li, Y. The impact of age difference on the efficacy and safety of COVID-19 vaccines: A systematic review and meta-analysis. Frontiers in immunology, 2021, 12.

Abulhassan Ali, Amogh Prabhakar, Akul Prabhakar, Aman Pal, Ying Yi Lim and Pramath Kakodkar, Charles Yap. Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic. Therapeutic Advances in Vaccines and Immunotherapy 2021; 9: 1–21.

6.World health organization. Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing 2022.https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1

7.World health organization (. Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19. https://apps.who.int/iris/bitstream/handle/10665/352124/WHO-2019-nCoV-vaccines-SAGE-recommendation-mRNA-1273-2022.1-eng.pdf?sequence=1&isAllowed=y

8.World health organization (March, 2022) Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzervria™, SII COVISHIELD™) https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1

9.World health organization( December, 2021) Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-Ad26.COV2.S-2021.1

10.world health organization. Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotic Group (‎CNBG)‎, Sinopharm2022.https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP




DOI: http://dx.doi.org/10.52155/ijpsat.v36.2.5020

Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 Abdelsalam Abuzreda, Amenh B. Yousif, Hanan Alsgheer

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.